Cargando…
Therapeutic Potential of Hyporesponsive CD4(+) T Cells in Autoimmunity
The interaction between dendritic cells (DCs) and T cells is crucial on immunity or tolerance induction. In an immature or semi-mature state, DCs induce tolerance through T-cell deletion, generation of regulatory T cells, and/or induction of T-cell anergy. Anergy is defined as an unresponsive state...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4585084/ https://www.ncbi.nlm.nih.gov/pubmed/26441992 http://dx.doi.org/10.3389/fimmu.2015.00488 |
_version_ | 1782392127665209344 |
---|---|
author | Maggi, Jaxaira Schafer, Carolina Ubilla-Olguín, Gabriela Catalán, Diego Schinnerling, Katina Aguillón, Juan C. |
author_facet | Maggi, Jaxaira Schafer, Carolina Ubilla-Olguín, Gabriela Catalán, Diego Schinnerling, Katina Aguillón, Juan C. |
author_sort | Maggi, Jaxaira |
collection | PubMed |
description | The interaction between dendritic cells (DCs) and T cells is crucial on immunity or tolerance induction. In an immature or semi-mature state, DCs induce tolerance through T-cell deletion, generation of regulatory T cells, and/or induction of T-cell anergy. Anergy is defined as an unresponsive state that retains T cells in an “off” mode under conditions in which immune activation is undesirable. This mechanism is crucial for the control of T-cell responses against self-antigens, thereby preventing autoimmunity. Tolerogenic DCs (tDCs), generated in vitro from peripheral blood monocytes of healthy donors or patients with autoimmune pathologies, were shown to modulate immune responses by inducing T-cell hyporesponsiveness. Animal models of autoimmune diseases confirmed the impact of T-cell anergy on disease development and progression in vivo. Thus, the induction of T-cell hyporesponsiveness by tDCs has become a promising immunotherapeutic strategy for the treatment of T-cell-mediated autoimmune disorders. Here, we review recent findings in the area and discuss the potential of anergy induction for clinical purposes. |
format | Online Article Text |
id | pubmed-4585084 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-45850842015-10-05 Therapeutic Potential of Hyporesponsive CD4(+) T Cells in Autoimmunity Maggi, Jaxaira Schafer, Carolina Ubilla-Olguín, Gabriela Catalán, Diego Schinnerling, Katina Aguillón, Juan C. Front Immunol Immunology The interaction between dendritic cells (DCs) and T cells is crucial on immunity or tolerance induction. In an immature or semi-mature state, DCs induce tolerance through T-cell deletion, generation of regulatory T cells, and/or induction of T-cell anergy. Anergy is defined as an unresponsive state that retains T cells in an “off” mode under conditions in which immune activation is undesirable. This mechanism is crucial for the control of T-cell responses against self-antigens, thereby preventing autoimmunity. Tolerogenic DCs (tDCs), generated in vitro from peripheral blood monocytes of healthy donors or patients with autoimmune pathologies, were shown to modulate immune responses by inducing T-cell hyporesponsiveness. Animal models of autoimmune diseases confirmed the impact of T-cell anergy on disease development and progression in vivo. Thus, the induction of T-cell hyporesponsiveness by tDCs has become a promising immunotherapeutic strategy for the treatment of T-cell-mediated autoimmune disorders. Here, we review recent findings in the area and discuss the potential of anergy induction for clinical purposes. Frontiers Media S.A. 2015-09-22 /pmc/articles/PMC4585084/ /pubmed/26441992 http://dx.doi.org/10.3389/fimmu.2015.00488 Text en Copyright © 2015 Maggi, Schafer, Ubilla-Olguín, Catalán, Schinnerling and Aguillón. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Maggi, Jaxaira Schafer, Carolina Ubilla-Olguín, Gabriela Catalán, Diego Schinnerling, Katina Aguillón, Juan C. Therapeutic Potential of Hyporesponsive CD4(+) T Cells in Autoimmunity |
title | Therapeutic Potential of Hyporesponsive CD4(+) T Cells in Autoimmunity |
title_full | Therapeutic Potential of Hyporesponsive CD4(+) T Cells in Autoimmunity |
title_fullStr | Therapeutic Potential of Hyporesponsive CD4(+) T Cells in Autoimmunity |
title_full_unstemmed | Therapeutic Potential of Hyporesponsive CD4(+) T Cells in Autoimmunity |
title_short | Therapeutic Potential of Hyporesponsive CD4(+) T Cells in Autoimmunity |
title_sort | therapeutic potential of hyporesponsive cd4(+) t cells in autoimmunity |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4585084/ https://www.ncbi.nlm.nih.gov/pubmed/26441992 http://dx.doi.org/10.3389/fimmu.2015.00488 |
work_keys_str_mv | AT maggijaxaira therapeuticpotentialofhyporesponsivecd4tcellsinautoimmunity AT schafercarolina therapeuticpotentialofhyporesponsivecd4tcellsinautoimmunity AT ubillaolguingabriela therapeuticpotentialofhyporesponsivecd4tcellsinautoimmunity AT catalandiego therapeuticpotentialofhyporesponsivecd4tcellsinautoimmunity AT schinnerlingkatina therapeuticpotentialofhyporesponsivecd4tcellsinautoimmunity AT aguillonjuanc therapeuticpotentialofhyporesponsivecd4tcellsinautoimmunity |